Cami Samuels joined Venrock in 2014 and focuses on healthcare with an emphasis on biotech, medical devices, and consumer health. She currently serves on the board of Spirox Medical and Unity Biotechnology, and recently stepped off the board of REGENXBIO (RGNX). Prior to Venrock, Cami was a Managing Director at Versant Ventures for a decade where she led investments in Achaogen (AKAO), Kythera (KYTH), Novacardia (acquired by Merck), and ParAllele (acquired by Affymetrix), among others. She was also a board observer at several companies including Genomic Health (GHDX), Fluidigm (FLDM), and Syrrx (acquired by Takeda).
Before Versant, she was responsible for business development at Tularik, Inc. (acquired by Amgen) where she in-licensed two of the company’s clinical-stage products and led Tularik’s Technology Acquisition Group. Before Tularik, Cami worked in corporate development at Genzyme and Millennium Predictive Medicine, and was a management consultant to healthcare and biotech companies at LEK Consulting.
Cami earned her Bachelor’s degree in Biology from Duke University and an MBA from Harvard Business School, where she graduated as a Baker Scholar. In 2002, The Aspen Institute named Camille a Henry Crown Fellow.